Research and Markets (http://www.researchandmarkets.com/reports/c90679)
has announced the addition of Cancer Biomarkers Conference 2008 to their
offering.
Cancer Biomarkers Development and Clinical Use
Overview:
The Cancer Biomarker 2008 Conference has been organized to provide a
critical examination of the latest in cancer diagnosis, as well as to
provide insight from key industry leaders concerning cutting-edge
technology platforms.
This conference will also provide a forum for leaders in cancer
biomarkers to share ideas, network with other delegates and advance
understanding of the potential of new cancer detection technologies.
Who Should Attend:
Cancer diagnostics company representatives.
In vitro diagnostic companies management and R&D directors.
Biotechnology companies.
Medical devices manufacturers.
Diagnostic laboratory directors and staff.
Leaders from the Following Areas Will Greatly Benefit from Attending:
Clinical Laboratory leaders.
Hospital CFOs and CSOs.
Physicians.
Cancer diagnostics developers.
Business development leaders.
Strategic planning and development personnel.
Technology development.
Marketing.
Research and development.
Key Themes:
A critical examination of key emerging biomarker technologies for
cancer diagnostics.
Formation of successful alliances.
Application of emerging technologies to cancer diagnostics.
Transitioning from laboratory in vitro diagnostics to clinical
management of cancer patients.
The emerging role of cancer diagnostic tests in personalized medicine.
The intersection of genomics and cancer diagnostics with personalized
medicine.
Questions Answered in the Conference:
What will the cancer diagnostics market be worth by the end of the
decade?
Which market key segments will drive cancer diagnostics market growth?
Which new technologies will reach the cancer diagnostics market in the
next 2-3 years?
How is technology innovation impacting the dynamics and direction of
the diagnostics industry?
How can clinical labs bring new cancer diagnostic tests to patent care?
What are the key challenges in gaining acceptance of new technologies
by users, payers and regulators?
How is technology innovation facilitating the transition of new cancer
diagnostics testing into standard healthcare practice?
Top Five Reasons To Attend the Conference:
Discover the cancer biomarkers sectors with the greatest prospective
growth, ensuring you can successfully align your future strategies
with predicted success.
Evaluate the competitive dynamics of the cancer biomarkers market and
understand the changing relationship between IVD companies and the
cancer diagnostics testing sector.
Identify the key players in the cancer biomarkers market, recognize
lucrative partnering opportunities and benchmark your strategies
against the leading players.
Assess opportunities and challenges faced by diagnostic companies in
gaining acceptance of innovative technologies by payers, regulators
and users.
Understand the factors driving growth of the cancer biomarkers market.
Date: Monday, June 16, 2008
Venue: The Yale Club of New York City
Location: 50 Vanderbilt Avenue directly across the street from Grand
Central Station between East 44th Street and East 45th Street (one block
east of Madison Avenue) New York, New York, U.S.A. 10017
Agenda:
7:15 am – 8:00 am Registration and Continental
Breakfast
8:00 am – 8:10 am Welcoming and Introductory
Remarks
Joseph Dooley, Ph.D., DABCC, FACB, CEO, TriMark Publications, LLC
8:10 am – 9:00 am Keynote Speaker –
Current Recommendations for Cancer Assays
Martin Fleisher, Ph.D., Chair, Dept. of Clinical Laboratories, Memorial
Sloan-Kettering Cancer Center
9:00 am – 9:30 am Clinical Use of Cancer
Markers
Ken Offit, M.D., Memorial Sloan-Kettering Cancer Center
9:30 am – 10:00 am How Genetics and Molecular
Assays Will Change the Diagnosis and Management of Prostate Cancer
Harry Rittenhouse, Ph.D., Senior Director Cancer Program, Gen-Probe, Inc.
10:00 am – 10:30 am Intermission –
Meet the Exhibitors
10:30 am – 11:00 am New Cancer Biomarkers and
Their Clinical Utility
Don Baakman, Abbott Diagnostics
11:00 am – 11:30 am Multimarker Panel Predicts
Risk of Ovarian Caner in Women with Pelvic Mass
W. Jeffrey Allard, Ph.D., Vice President, Clinical Affairs & Business
Development, Fujirebio, Inc.
11:30 am – 12:00 pm Monitoring Circulating
HER-2/neu Levels In MBC Patients Treated with HER-2/neu Inhibitors
Walt Carney, Ph.D., Head, Siemens Medical Solutions Diagnostics,
Oncogene Science Biomarker Group
12:00 pm – 1:00 pm Seated Luncheon in Dining
Room
1:00 pm – 1:30 pm Bringing New Cancer Assay
Technologies into the Lab
Herbert Fritsche, Ph.D., Professor and Chief, Clinical Chemistry;
Chairman, Scientific Advisory Board, MD Anderson Cancer Center
1:30 pm – 2:00 pm AviaraDx Technology
Platform in Ovarian Cancer
Carol Berry, AviaraDx, Inc.
2:00 pm – 2:30 pm Using Gene Expression
Assays to Guide Therapy in Cancer Patients
Richard Bender, MD, Medical Director, Hematology/Oncology, Quest
Diagnostics, Inc.
2:30 pm – 3:00 pm Oncotype DXTM Breast Cancer
Assay: Lessons Learned from Three Years on the Market
Gary Palmer, Senior Director, Medical Affairs, Genomic Health, Inc.
3:00 pm – 3:30 pm Development of High-Value
Diagnostic Assays in Ovarian Cancer and Peripheral Arterial Disease
Eric Fung, Ph.D., Vice President and CSO, Vermillion, Inc.
3:30 pm – 4:00 pm Intermission
4:00 pm – 4:30 pm Utilizing Urinary Protein
Biomarkers for Managing Cancer Survivors
Anthony Shuber, Ph.D., Chief Technical Officer, Predictive Biosciences,
Inc.
4:30 pm – 5:00 pm Cancer Biomarker Development
John Langmore, Ph.D., Vice President of Commercial Development, Rubicon
Genomics, Inc.
5:00 pm – 5:30 pm Regulatory Perspectives on
Cancer Biomarkers
Kaiser J. Aziz, Ph.D., FACB, FACS, Director, KJ Biomedical Consulting,
LLC
5:30 pm – 6:30 pm Reception
For more information visit http://www.researchandmarkets.com/reports/c90679
|